z-logo
Premium
Characterization of two cell lines, derived from two malignant fibrous histiocytomas
Author(s) -
Roholl P. J. M.,
Kleyne J.,
Van Blokland M.,
Spies P. L.,
Rutgers D. H.,
AlbusLutter Ch. E.,
Van Unnik J. A. M.
Publication year - 1986
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1711500204
Subject(s) - histogenesis , histiocyte , pathology , mesenchymal stem cell , biology , staining , cell culture , cell , giant cell , in vitro , histology , progenitor cell , immunohistochemistry , stem cell , medicine , microbiology and biotechnology , biochemistry , genetics
We have investigated the phenotype and ultrastructure of tumour cells from two cell lines each derived from a malignant fibrous histiocytoma (MFH) as a means of studying the histogenesis of this group of tumours. The first MFH (MFH‐I) was of the pleomorphic subtype, with a predominantly histiocytic appearance, the second was of the pleomorphic subtype associated with myxoid and storiform areas (MFH‐II). In vitro tumour cells from both neoplasms showed aberrant growth properties. Xenografts in nude mice from both neoplasms showed a similar histology to that of the original tumour. Both tumours showed hyaluronidase sensitive alcian blue staining. Phenotypic studies of the two cell lines and of the tumour tissues demonstrated that the cells differed in the presence of collagen types I and III. They did not show evidence of histiocytic, endothelial, leiomyoblastic, rhabdomyoblastic, lipoblastic of schwannian origin. Ultrastructurally, the two cell lines were found to be different. In vitro and in xenografts the cell type of MFH‐I resembled a primitive mesenchymal cell. Whereas that of MFH‐II resembled a fibroblast‐like cell. We concluded that the group of MFH is heterogeneous and is probably derived from more than one progenitor cell.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here